Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D.
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D.
-
Narrated by:
-
By:
About this listen
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
During their conversation, Dr. Morice and Dr. Tan explore:
- Inspiration for developing the liquid biopsy.
- Features that differentiate LiquidHALLMARK® from existing cancer tests.
- Patients who will benefit from the test and how an oncologist might use the results.
- The future potential of liquid biopsy advancements.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet